Innovations - HVI-TMC
Since 1927, researchers and clinicians at Memorial Herman-Texas Medical Center (TMC) have been bringing groundbreaking discoveries in heart and vascular treatments from the laboratory to the bedside.
From research isolating the genetic origins of life-threatening thoracic aortic aneurysms to advanced imaging technology that allows cardiologists to detect heart disease early enough to reverse it, the Heart & Vascular Institute-Texas Medical Center continues to build upon its strong track record of innovation leading to outstanding outcomes and is poised to become one of the nation's leading heart and vascular hospitals.
The high-quality care provided by our affiliated physicians, nurses and other clinical staff has earned Memorial Hermann Heart & Vascular Institute-Texas Medical Center the distinction of being ranked among the nation's top 40 hospitals for heart care and heart surgery in U.S. News & World Report's 2011 Top-Ranked Hospitals for Cardiology & Heart Surgery.
Physicians affiliated with Memorial Hermann Heart & Vascular Institute-Texas Medical Center were the first in the world to perform robotic-assisted reconstructive surgery, the first in the world to show that heart disease can be reversed, the first in Texas to give patients thrombolytics, the first in Texas to offer cardiac risk screening design specifically for women and the first in Houston to perform minimally invasive surgery to correct atrial fibrillation.
Lifesaving heart attack treatments developed by doctors at the Institute have reduced the average time it takes to open occluded arteries and restore blood flow to the heart to well below the Joint Commission standard, saving lives and reducing damage to the heart.
The first PET scanner capable of imaging the entire heart was developed at the Weatherhead PET Center for Preventing and Reversing Atherosclerosis in 1979, and PET imaging remains the most accurate technology for identifying early or advanced blood flow abnormalities in the heart, including minor changes caused by early coronary artery disease.